Meeting
2019 Gastrointestinal Cancers Symposium
The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
Authors
Chihiro Kosugi
Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan
Chihiro Kosugi , Hirohiko Kamiyama , Yoichiro Yoshida , Hiroshi Yoshida , Keiichiro Ishibashi , Keisuke Ihara , Makoto Takahashi , Hidekazu Kuramochi , Hiromichi Sonoda , Kazuhiko Yoshimatsu , Atsuko Fukazawa , Akihisa Matsuda , Satoru Yamaguchi , Hideyuki Ishida , Suguru Hasegawa , Takeshi Yamada , Kazuo Narushima , Kiyohiko Shuto , Kazuhiro Sakamoto , Keiji Koda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000022438
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 614)
DOI
10.1200/JCO.2019.37.4_suppl.614
Abstract #
614
Poster Bd #
J17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world comparison of low- versus high-dose continuous 5FU infusion in patients receiving triplet chemotherapy plus bevacizumab for newly diagnosed metastatic colorectal cancer (mCRC).
First Author: William Joseph Chapin
Poster
2023 ASCO Annual Meeting
Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).
First Author: Timothy Jay Price
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz